Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy... July 12, 2024 ΚΑΡΚΙΝΟΣ ΤΩΝ ΟΣΤΩΝ February 10, 2019 Breast Cancer Survivor is Swimming the English Channel to Benefit Mental... July 5, 2021 The path to least resistance: How our researchers are outsmarting cancer’s... May 25, 2022 Load more HOT NEWS Fostering Black leadership in cancer research Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... Updated Nutrition Facts Label Reflects Science on Diet and Health, including... Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed...
